XERS - EMA backs Xeris Pharma's Ogluo as treatment in severe hypoglycaemia shares +8%

The European Medicines Agency's advisory group CHMP has adopted a positive opinion for Xeris Pharmaceuticals' (XERS) Ogluo (glucagon) recommending Ogluo for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The European Commission will review the recommendation, and a final decision on the marketing application is expected in Q1 2021.If approved, Ogluo is expected to be launched in certain European countries in H2 2021.Shares up 8% premarket.

For further details see:

EMA backs Xeris Pharma's Ogluo as treatment in severe hypoglycaemia, shares +8%